

With the patronage of



SIE
Società Italiana di Ematologia



Current Challenges in Hematology – 2nd Edition

Rome, 24-25 January 2024

NH VITTORIO VENETO

Corso d'Italia, 1, Rome

PRESIDENT

Alessandro Isidori

HONORARY PRESIDENTS

Giuseppe Visani

Adolfo de la Fuente Buergera

ORGANIZING COMMITTEE

Naval Daver

Felicetto Ferrara

Yngvar Floisand

Uwe Platzbecker

Giuseppe Visani

Umberto Vitolo

Elena Zamagni

January 24th 2024

09.00 Congress open
Alessandro Isidori

09.15 SESSION I - SALA TIZIANO MULTIPLE MYELOMA

Chairmen: Maria Victoria Mateos, Elena Zamagni

09.15 Biology of high-risk disease
Alessandra Romano • Catania

09.30 Management of high-risk patients
Roberto Mina • Turin

09.45 Bispecific antibodies and CAR-T:
data from clinical trials
Maria Victoria Mateos • Salamanca

10.00 Practical management of patients
treated with bispecific antibodies and CAR-T
Elena Zamagni • Bologna

10.15 Anti-BCMA targeted therapy in RRMM:
data from real life
Maria Teresa Petrucci • Rome

10.30 Discussion

10.45 SESSION II LYMPHOMAS - HOW TO INCORPORATE NEW DRUGS IN CLINICAL PRACTICE

Chairmen: Umberto Vitolo, Maurizio Martelli

10.45 Brentuximab Vedotin
Luigi Rigacci • Rome

11.00 Polatuzumab Vedotin
Maurizio Martelli • Rome

11.15 Tafasitamab
Guido Gini • Ancona

11.30 Epcoritamab
Umberto Vitolo • Turin

11.45 Zanubrutinib
Alessandra Tedeschi • Milan

12.00 Mosunetuzumab
Marco Ladetto • Alessandria

12.15 Discussion

12.30 - 13.30 SALA MASCAGNI

LUNCH MEETING JANSSEN NO ECM

New frontiers in target therapies for CLL
Chairmen: Alessandro Isidori, Antonio Cuneo

12.30 Introduction
Alessandro Isidori • Pesaro

12.35 The future of CLL patient management: a
solid and innovative approach
Luca Laurenti • Rome
Paolo Sportoletti • Perugia

13.15 Discussion

13.45 - 14.45 SALA MASCAGNI SIMPOSIO ABBVIE NO ECM

How to face current challenges in AML,
DLBCL, CLL?
Chairman: Alessandro Isidori

13.45 AML: How to improve outcomes in
unfit patients through an optimal
Ven+Aza management
Carmela Gurrieri • Padua

14.00 CLL: The benefits of fixed duration
Ven based regimens in both fit and
unfit patients' settings
Alessandro Sanna • Florence

14.15 DLBCL: Epcoritamab and Bispecific
Antibodies: Transforming the Care of
R/R DLBCL Patients
Gerardo Musuraca • Meldola

14.30 Discussion Q&A

14.45 - 15.30 SALA MASCAGNI SIMPOSIO ASTRAZENECA NO ECM

Introduzione Alessandro Isidori

Il profilo farmacologico di Acabrutinib:
l'integrazione di efficacia e sicurezza
Romano Danesi • Pisa
Marzia Varettoni • Pavia

SALA TIZIANO

16.00 Lecture: CAR-T: new paradigm in DLBCL ?
Paolo Corradini • Milan

16.15 SESSION III - SALA TIZIANO CHALLENGES IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: Francesca Romana Mauro, Antonio Cuneo

16.15 Therapeutic options in CLL: first line
Francesca Romana Mauro • Rome

16.30 Therapeutic options in CLL: subsequent lines
Antonio Cuneo • Ferrara

16.45 Looking at the future: evolution of the treatment
Othman al Sawaf • Cologne

17.00 Clinical management of patients with CLL
Paolo Sportoletti • Perugia

17.15 Discussion

17.30 SESSION IV MYELOPROLIFERATIVE NEOPLASMS

Chairmen: Francesco Passamonti, Massimo Breccia

17.30 Current challenges in polycythemia vera
Francesco Passamonti • Milan

17.45 New kids on the block:
rusfertide in polycythemia vera
Alessandro Isidori • Pesaro

18.00 Current management of patients with
myelofibrosis
Massimo Breccia • Rome

18.15 New drugs
Giuseppe Palumbo • Catania

18.30 Discussion

18.45 Day-1 Closing

19.00 - 20.00 SALA MASCAGNI SIMPOSIO BEIGENE NO ECM

**Le nuove evidenze dei BTKi nel trattamento
del paziente ematologico**

19.00 Introduzione
A. Tedeschi • Milan

19.05 Linfomi indolenti
G. Gini • Ancona

19.20 Macroglobulinemia di Waldenstrom
A. Tedeschi • Milan

19.35 Ruolo dei BTKi nella Leucemia
Linfatica Cronica
G. Loseto • Bari

19.50 Conclusioni
A. Tedeschi • Milan

January 25th 2024

Sponsored lecture by SYROS NO ECM

Updates on the use of retinoids in MDS and AML

9.00 Retinoic acid receptor alpha and Tamibarotene

Roberto Russo · MSL Italia Syros

9:15 Tamibarotene Clinical data in MDS and AML

Alessandro Isidori · Pesaro

09.30 SESSION V MYELODISPLASTIC SYNDROMES

Chairmen: Maria Teresa Voso, Eunice Wang

09.30 Prognosis: From to MDS

Maria Teresa Voso · Rome

09.45 Therapy: Standards and perspectives

Lionel Ades · Paris

10.00 Iron in MDS

Francesca Vinchi · New York

10.15 Immunotherapy in myeloid malignancies

Naval Daver · Houston

10.30 Discussion

10.40 Lecture: Challenges in treatment of immune thrombocytopenia (ITP)

Elena Rossi · Rome

10.55 Coffee Break

11.15 SESSION VI ACUTE MYELOID LEUKEMIA

Chairmen: Naval Daver, Konstanze Dohner

11.15 Integrating new AML classifications in clinical practice

Konstanze Dohner · Ulm

11.30 Treatment of high-risk AML

Alessandro Isidori · Pesaro

11.45 Mechanism of resistance and novel combinations with Venetoclax-based treatment in AML

Naval Daver · Houston

12.00 Targeting FLT-3 mutated AML

Alexander Perl · Philadelphia

12.15 Menin inhibition in acute leukemias

Eunice Wang · Buffalo

12.30 Discussion

12.40 Light Lunch

12.30 - 13.30 LUNCH SYMPOSIUM CURIS NO ECM

12.30 Welcome & Introduction

Alessandro Isidori · Pesaro

12.35 IRAK4 Pathway and Inhibition

Alessandro Isidori · Pesaro

12.50 Clinical Activity:

TakeAim Leukemia

TakeAim Lymphoma

Adolfo de la Fuente Buergera · Madrid

13.20 Discussion & Conclusions

Alessandro Isidori

Adolfo de la Fuente Buergera

13.30 SESSION VII ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: Sabina Chiaretti, Cristina Papayannidis

13.30 New treatment strategies for Ph-like ALL

Sabina Chiaretti · Rome

13.45 Antibodies in MRD +ve ALL

Cristina Papayannidis · Bologna

14.00 CAR-T in childhood ALL: history of a revolution

Franco Locatelli · Rome

14.15 Discussion

14.30 SESSION VIII

ACUTE MYELOID LEUKEMIA (II)

Chairmen: Felicetto Ferrara, Adriano Venditti

14.30 MRD and treatment decision making
Adriano Venditti • Rome

14.45 Fitness and treatment decision making in
patients not eligible for intensive chemotherapy
Felicetto Ferrara • Naples

15.00 Targeting IDH1 and IDH 2
Adolfo de la Fuente Buergera • Madrid

15.15 Maintenance therapy
Giuseppe Visani • Pesaro

15.30 SESSION IX

STEM CELL TRANSPLANTATION

Chairmen: Yngvar Floisand, Alessandro Isidori

15.30 Which AML patients should we transplant in 2023?
Yngvar Floisand • Oslo

15.45 Treosulfan-based conditioning regimen: a new
paradigm?
Michele Malagola • Brescia

16.00 Diagnosis and treatment of VOD/SOS after allo-HSCT
Simona Sica • Rome

16.15 Discussion

16.30 Congress Close
SEE YOU IN 2025

CME INFO & REGISTRATION

Event n. 2773 - 366183 - Objective n. 3

13 CME Credits for : Hematologists and Biologists

Free registration: www.proeventi.it

pin : current2024 (DEPP ECM APP)

provider n. 2773



www.proeventi.it

info@proeventi.it

WITH THE UNRESTRICTED EDUCATIONAL GRANT OF

DIAMOND SPONSOR

abbvie

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

SILVER SPONSOR

AMGEN

AstraZeneca

BeiGene

Incyte

Jazz Pharmaceuticals

BRONZE SPONSOR

Bristol Myers Squibb

CURIS

KURA ONCOLOGY

GILEAD

medac PHARMA

JD LABORATOIRES DELBERT

Protagonist Therapeutics

prothena

Roche

SERVIER
moved by you

SYROS

NOVARTIS

Takeda